Clinton Musil joined Personalis in January 2019 as Chief Business Officer. Mr. Musil previously worked at ARMO Biosciences, where he oversaw the Company’s $147 million initial public offering and $1.6 billion sale to Eli Lilly. Clinton has expertise in corporate finance and mergers and acquisitions (M&A) from the healthcare industry, including raising several billion dollars [...]
2018 SITC: Improving Neoantigen Identification for Therapeutic and Diagnostic Use in Immuno-Oncology Using Mass Spectrometry and Machine Learning Neoantigens are increasingly critical in immuno-oncology as therapeutic targets for neoantigen-based personalized cancer vaccines (PCVs) and as potential biomarkers for immunotherapy response. However, the methods for identifying which neoepitopes are more likely to provoke an immune [...]
2018 AACR: Methods of Improving Accuracy of Neoantigen Identification for Therapeutic and Diagnostic Use in Immuno-oncology Neoantigens are increasingly critical in immuno-oncology as a therapeutic target for neoantigen-based personalized cancer vaccines and as a potential biomarker for immunotherapy response. However, the methods for identifying which neoepitopes are more likely to provoke an immune response remains [...]
2018 AACR: Supporting Neoantigen Discovery and Monitoring in Plasma Through Analytical Validation of a Deep Augmented Content Enhanced (ACE) Exome Neoantigens are increasingly critical in immuno-oncology as a therapeutic target for neoantigen-based personalized cancer vaccines and as a potential biomarker for immunotherapy response. An important step in identifying neoantigens is comprehensive exome and transcriptome [...]
2018 AACR: Molecular Profiling of Anti-PD-1 Treated Melanoma Patients Reveals Importance of Assessing Neoantigen Burden and Tumor Escape Mechanisms for Clinical Treatment Despite the remarkable response of some melanoma patients to checkpoint inhibitor therapy, significant numbers of patients do not achieve complete response. To understand this differential response, there is an increasing interest in [...]
2018 AACR: Deconvolution of diverse immune cell populations within tumors using ACE Transcriptome Comprehensive tumor immuno-genomic characterization is becoming an important tool for identifying new biomarkers correlated with patient response to immunotherapy. Both the abundance and composition of tumor-infiltrating immune cells have been associated with tumor progression and patient outcome. There is interest in [...]
NeoantigenID™ An analytical module of the ImmunoID NeXT PlatformTM Comprehensive Identification of Putative Neoantigens Neoantigens are mutated peptides that are expressed by tumor cells, but not by normal tissue. As a result, they can be recognized as foreign antigens by cells of the immune system — making them promising [...]
ImmunogenomicsID An analytical module of the ImmunoID NeXT PlatformTM Comprehensive Immunogenomic Characterization ImmunogenomicsIDTM, an analytical module of the ImmunoID NeXT Platform, characterizes critical areas of tumor and immune biology such as the antigen processing machinery (APM), human leukocyte antigens (HLA), checkpoint modulation, tumor escape mechanisms, the adaptive and innate [...]
ImmunoID NeXT™ The Universal Cancer Immunogenomics Platform Advancing Modern Precision Oncology The ImmunoID NeXT Platform is designed specifically to enable the development of more efficacious cancer immunotherapies. While the success of checkpoint blockade has been hugely promising, it’s increasingly apparent that predicting response to immunotherapies and developing new ones [...]
Xtalks Webinar Neoantigens for Personalized Cancer Vaccines-Comprehensive Identification and Effective Selection Developing effective personalized cancer vaccines depends on comprehensively detecting all neoantigens in a tumor sample and then selecting the neoantigens that are most likely to be effective in an individual patient. This process, especially under the timeline demands of clinical trials or [...]
